Literature DB >> 12393902

MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination.

James C Badciong1, Arthur L Haas.   

Abstract

It has been well documented that Mdm2 and its homologue MdmX not only are critical negative regulators of the tumor suppressor p53 but that both Mdm2 and MdmX interact to affect the function of the other. The mechanisms through which these effects are manifested, however, remain unclear. Although Mdm2 has been established as a RING finger ubiquitin ligase, MdmX has not been shown to possess this activity despite the extensive sequence homology between their respective RING finger domains. Here we demonstrate that MdmX acts as a ubiquitin ligase in vitro, being capable of autoubiquitination, as well as mediating the ubiquitination of p53. The addition of Mdm2 to in vitro ubiquitination assays containing MdmX results in a synergistic increase of ubiquitin conjugation. Analysis of the resulting ubiquitin conjugates reveals that this observed synergy reflects an increase in Mdm2 ubiquitination. This study also suggests that ubiquitination of Mdm2 and MdmX may not serve as a signal for degradation, as we show that each are capable of synthesizing non-lysine 48 polyubiquitin chains and, in fact, utilize multiple lysine linkages. Taken together, these findings suggest a more active role for MdmX in the Mdm2-MdmX-p53 regulatory network than has been proposed previously.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393902     DOI: 10.1074/jbc.M208593200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  E1-E2 interactions in ubiquitin and Nedd8 ligation pathways.

Authors:  Zeynep Tokgöz; Thomas J Siepmann; Frederick Streich; Brajesh Kumar; Jennifer M Klein; Arthur L Haas
Journal:  J Biol Chem       Date:  2011-11-08       Impact factor: 5.157

2.  Turning the RING domain protein MdmX into an active ubiquitin-protein ligase.

Authors:  Saravanakumar Iyappan; Hans-Peter Wollscheid; Alejandro Rojas-Fernandez; Andreas Marquardt; Hao-Cheng Tang; Rajesh K Singh; Martin Scheffner
Journal:  J Biol Chem       Date:  2010-08-12       Impact factor: 5.157

Review 3.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

4.  The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance.

Authors:  Christian Kannemeier; Rong Liao; Peiqing Sun
Journal:  Mol Biol Cell       Date:  2007-04-11       Impact factor: 4.138

5.  Age-related retinal degeneration (arrd2) in a novel mouse model due to a nonsense mutation in the Mdm1 gene.

Authors:  Bo Chang; Md Nawajes A Mandal; Venkata R M Chavali; Norman L Hawes; Naheed W Khan; Ronald E Hurd; Richard S Smith; Muriel L Davisson; Laura Kopplin; Barbara E K Klein; Ronald Klein; Sudha K Iyengar; John R Heckenlively; Radha Ayyagari
Journal:  Hum Mol Genet       Date:  2008-09-18       Impact factor: 6.150

6.  MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination.

Authors:  Xinjiang Wang; Junru Wang; Xuejun Jiang
Journal:  J Biol Chem       Date:  2011-05-13       Impact factor: 5.157

7.  Mdm2 and Mdm4 loss regulates distinct p53 activities.

Authors:  Juan A Barboza; Tomoo Iwakuma; Tamara Terzian; Adel K El-Naggar; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

8.  Mechanism of p53 stabilization by ATM after DNA damage.

Authors:  Qian Cheng; Jiandong Chen
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

9.  Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway.

Authors:  C S Busso; T Iwakuma; T Izumi
Journal:  Oncogene       Date:  2009-02-16       Impact factor: 9.867

10.  Controlling the Mdm2-Mdmx-p53 Circuit.

Authors:  David L Waning; Jason A Lehman; Christopher N Batuello; Lindsey D Mayo
Journal:  Pharmaceuticals (Basel)       Date:  2010-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.